| Autor: |
Freedman, Mark S., Morawski, Julia, Thangavelu, Karthinathan |
| Zdroj: |
Multiple Sclerosis Journal - Experimental, Translational & Clinical; Apr-Jun2018, Vol. 4 Issue 2, p1-5, 5p, 1 Chart, 1 Graph |
| Abstrakt: |
Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48–173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying therapies for multiple sclerosis, which typically have a fixed 2-year duration. This communication reports clinical outcomes in TOWER over a fixed 2-year period. Reductions in annualised relapse rates and 12-week confirmed disability worsening associated with teriflunomide were comparable between overall intent-to-treat and fixed 2-year study populations in TOWER. Consistency in outcomes supports the inclusion of TOWER data in comparative analyses with other disease-modifying therapies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
